CBD reduced seizures for up to 3 years in children with treatment-resistant epilepsy in Georgia

Over 36 months, 45 children with treatment-resistant epilepsy (various etiologies beyond Dravet/LGS) treated with adjunctive CBD (Epidiolex, up to 50 mg/kg/day) showed statistically significant reductions in seizure frequency at months 3, 6, 12, 18, 24, and 36. Seizure-free days increased by an average of 7.52 days (p<0.001). Higher doses (>25 mg/kg/day) were associated with more adverse events initially, though AE rates decreased over time.

Multicenter expanded access program in Georgia for children aged 1-18 with treatment-resistant epilepsy who had failed available treatments and were ineligible for Dravet/LGS RCTs. CBD titrated to 25 mg/kg/day with optional increase to 50 mg/kg/day. 36-month follow-up.

Most CBD epilepsy data comes from Dravet and Lennox-Gastaut syndrome. This study extends the evidence to children with diverse seizure etiologies who failed all other treatments, showing benefit for a broader population.

This is one of the longest follow-up studies of CBD for epilepsy. The sustained benefit over 3 years addresses a key clinical question: does CBD continue working long-term, or does tolerance develop? These data suggest sustained efficacy.

No control group (expanded access design); relatively small sample; mixed epilepsy etiologies make subgroup analysis difficult; seizure diaries may have reporting variability; state-specific program.